Clinical Trials
12 trialsNCT06150664 2026-04-20
A Phase 1 of CTX-8371 in Patients With Advanced Malignancies
Compass Therapeutics
Phase 1 Recruiting
NCT06451497 2026-04-02
This is a Phase 1 Trial of ZM008, an Anti-LLT1 Antibody, Used as Single Agent Followed by Combination Treatment With Toripalimab in Patients With Advanced Solid Tumors
Zumutor Biologics Inc.
Phase 1 Recruiting
NCT06022029 2025-12-24
ON-5001
OncoNano Medicine, Inc.
Phase 1 Recruiting
NCT05107674 2025-09-09
A Study of NX-1607 in Adults With Advanced Malignancies
Nurix Therapeutics, Inc.
Phase 1 Recruiting
NCT04254107 2025-02-10
A Safety Study of SEA-TGT (SGN-TGT) in Advanced Cancer
Seagen Inc.
Phase 1 Terminated
NCT03454451 2023-12-21
CPI-006 Alone and in Combination With Ciforadenant and With Pembrolizumab for Patients With Advanced Cancers
Corvus Pharmaceuticals, Inc.
Phase 1 Completed
NCT02706392 2022-08-31
Genetically Modified T-Cell Therapy in Treating Patients With Advanced ROR1+ Malignancies
Fred Hutchinson Cancer Center
Phase 1 Terminated
NCT03205176 2021-05-06
AZD5153 in Patients With Relapsed or Refractory Solid Tumors, Including Lymphomas
AstraZeneca
Phase 1 Completed
NCT03291938 2020-11-24
IACS-010759 in Advanced Cancers
M.D. Anderson Cancer Center
Phase 1 Completed
NCT03538028 2020-10-30
A Safety and Tolerability Study of INCAGN02385 in Select Advanced Malignancies
Incyte Corporation
Phase 1 Completed
NCT02576665 2020-02-07
A Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC in Patients With Solid Tumors or Lymphoma (Toca 6)
Tocagen Inc.
Phase 1 Terminated
NCT01986426 2018-10-03
LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab
Lytix Biopharma AS
Phase 1 Completed